Skip directly to content

Two unprecedented political opportunities are rapidly approaching– the Global Ministerial Conference and the UN High Level Meeting on TB. Civil society and community groups have a critical role to play in raising the profile and understanding of the issues we face in TB among government officials and ensuring that the commitments they make at high-level meetings are translated into urgent investments and actions.

To facilitate engagement between civil society and community groups and national policy makers, TAG has created tools and resources to

Deputy Executive Director – Development and Operations
Treatment Action Group

October 4, 2017

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.

TAG seeks a Deputy Executive Director for Development and Operations who will report directly to and work closely with the Executive Director, the senior staff, the administrator, other staff and consultants, and the Board of Directors and its committees.

Key Responsibilities:

  • Hire


On Tuesday October 3, members of the Health Subcommittee of the House Energy and Commerce (E&C) Committee will hold a hearing on “Examining Patient Access to Investigational Drugs.” In this hearing, a dangerous actthe Compassionate Freedom of Choice Act of 2017 (H.R. 1020) will be debated (a similar bill, The Right to Try Act of 2017, or S.204, already passed the Senate early this August).

Despite their catchy names, these acts offer only false hope: they won’t do anything to compel companies to make their experimental drugs and devices available pre-approval.

October 3, 2017

The Honorable Michael C. Burgess, MD
Chairman, Health Subcommittee
Energy and Commerce Committee
United States House of Representatives
Washington, DC 20515

The Honorable Gene Green
Ranking Member, Health Subcommittee
Energy and Commerce Committee
United States House of Representatives
Washington, DC 20515

Dear Chairman Burgess and Ranking Member Green:

Treatment Action Group (TAG) appreciates the opportunity to submit these comments to the Health Subcommittee of the U.S.

HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials

September 27, 2017 – The effectiveness of pre-exposure prophylaxis (PrEP) with the antiretroviral drug combination TDF/FTC (Truvada) raises questions regarding the design and conduct of trials of other candidate biomedical HIV prevention interventions, such as vaccines, passive immunization and alternative forms of PrEP. This white paper, made possible with support from Aidsfonds, summarizes the recommendations that have been published in the scientific literature to date, and highlights results from a survey on the topic targeted to

September 20, 2017, New York, NY—The Government of Malaysia reaffirmed its commitment to affordable access to hepatitis C treatment by issuing a compulsory license on sofosbuvir (Sovaldi). TAG lauds this landmark decision for enabling the entry of generic competition, which will effectively reduce prices.

Malaysian civil society organizations, including Third World Network, Malaysian AIDS Council, and Positive Malaysian Treatment Access and Advocacy Group, have tirelessly pushed for expanded access to direct-acting antivirals (DAAs) in the public health sector. Last month, Gilead announced

TB Activist Toolkits

August 2017

This 2017 update to the TB/HIV Activist Toolkit modules continues to build and provide fundamental information about tuberculosis (TB) in order to strengthen global advocacy and scientific literacy around TB and TB/HIV.

These toolkits cover important base knowledge on TB  and TB/HIV, as well as strategies to support advocacy across diagnostics, treatments, and prevention for TB. We hope that activists and others will use this information to inform their advocacy and to develop community education materials and sessions on TB.

An Activist's Guide to the TB LAM Test

September 2017 

As tuberculosis (TB) has risen to become the leading infectious killer of people living with HIV (PLHIV), diagnostic tests such as the TB LAM test are critically important to ensure diagnosis of TB quickly for this vulnerable population. LAM represents the only current point-of-care TB diagnostic test overall, that is specifically used for detecting TB in PLHIV with low CD4 counts. 

An Activist's Guide to the TB LAM Test provides important messaging and strategies to support in-country LAM advocacy and activism.

By Richard Jefferys, Project Director

On September 19th, 2013, the National Institute of Allergy and Infectious Diseases (NIAID) sponsored a daylong mini-summit to discuss the safety of adenovirus vaccine vectors in populations at risk for HIV infection.